Inventor · disambiguated record
C. Thomas Caskey
Also filed as: CASKEY C T · CASKEY C THOMAS
11 granted patents·3 pending applications·205 citations·filing 1991–2005
90Inventor score
Top patents by PatentIndex Score
14 records- 0173US5985846AGene therapy for muscular dystrophyBAYLOR COLLEGE MEDICINE·Filed 1995·Granted Nov 16, 1999·43 cites·2 claims
- 0272US6153379AParallel primer extension approach to nucleic acid sequence analysisBAYLOR COLLEGE MEDICINE·Filed 1994·Granted Nov 28, 2000·56 cites·22 claims
- 0371US7001722B1Parallel primer extension approach to nucleic acid sequence analysisPHARMACIA BIOTECH AB·Filed 2000·Granted Feb 21, 2006·2 cites·12 claims
- 0469US6001816AGene therapy for leptin deficiencyMERCK & CO INC·Filed 1997·Granted Dec 14, 1999·34 cites·3 claims
- 0556US5552282ADiagnosis of myotonic muscular dystrophyBAYLOR COLLEGE MEDICINE·Filed 1993·Granted Sep 3, 1996·25 cites·17 claims
- 0656US2003082613A1Parallel primer extension approach to nucleic acid sequence analysisBAYLOR COLLEGE MEDICINE·Filed 2002·Application pending·0 cites
- 0750US6180337B1Diagnosis of the fragile X syndromeBAYLOR COLLEGE MEDICINE·Filed 1991·Granted Jan 30, 2001·17 cites·9 claims
- 0845US6107025ADiagnosis of the fragile X syndromeBAYLOR COLLEGE MEDICINE·Filed 1991·Granted Aug 22, 2000·13 cites·4 claims
- 0945US2003215423A1Gene therapy for obesityMERCK & CO INC·Filed 2003·Application pending·0 cites
- 1045US2006105364A1Best's macular dystrophy genePETRUKHIN KONSTANTIN·Filed 2005·Application pending·0 cites
- 1144US6630346B1Gene therapy for obesityMERCK & CO INC·Filed 1997·Granted Oct 7, 2003·13 cites·7 claims
- 1234US6258944B1OB receptor isoforms and nucleic acids encoding themMERCK & CO INC·Filed 1997·Granted Jul 10, 2001·1 cites·28 claims
- 1333US7005290B1Best's macular dystrophy geneMERCK & CO INC·Filed 1999·Granted Feb 28, 2006·1 cites·5 claims
- 1430US6281346B1Rat ob-receptors and nucleotides encoding themMERCK & CO INC·Filed 1997·Granted Aug 28, 2001·0 cites·16 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →